Treatment of acute nonlymphocytic leukemia in adults: response to 2,2-anhydro-1-B-D-arabinofuranosyl-5-fluorocytosine and thioguanine on the L-12 protocol.
Fifty-one adult patients with acute nonlymphocytic leukemia (excluding acute promyelocytic leukemia) were treated on the L-12 protocol. The L-12 differed from the preceding L-6 in that 2,2-anhydro-1-B-D-arabinofuranosyl-5-fluorocytosine (AAFC), replaced arabinosylcytosine (ara-C) together with 6-thioguanine (TG) for remission induction. Achievement of remission was followed by an extended 14-week multi-drug consolidation program. With this more intense regimen, an overall complete remission rate of 49% and a median remission duration of 23.7 months were achieved; these results were not significantly better than the 57% complete remission rate and 8.6 months median remission duration obtained with the L-6 regimen. Four year disease-free survival was 22% on the L-12 compared with 16% on the L-6 protocol. No relationship between prognosis and FAB classification was found on either the L-6 or the L-12 protocol.
D000293:Adolescent; D000328:Adult; D000368:Aged; D003504:Ancitabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001428:Bacterial Vaccines / Q000008:administration & dosage; D003561:Cytarabine / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011550:Pseudomonas aeruginosa; D011897:Random Allocation; D013866:Thioguanine / Q000008:administration & dosage* / Q000009:adverse effects
D000970:Antineoplastic Agents; D001428:Bacterial Vaccines; D003561:Cytarabine; C011168:5-fluoro-2,2'-cyclocytidine; D003504:Ancitabine; D013866:Thioguanine